Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This two-phase project seeks to examine the cardiovascular response to consumption of cannabis variants of different cannabinoid composition through different methods (smoking vs. vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to predict risk factors for chronic-disease and negative health outcomes will be assessed following cannabis consumption at rest or in combination with exercise. These techniques will examine arterial stiffness, vascular function, and cardiac function. In phase I and II, subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis + exercise visits. Cannabis used in phase I of this study will consist of approximately 10% THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography measures will be performed following cannabis consumption by smoking or vaporizing, and cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle ergometer. Phase II of the study will implore a similar design. In favor of altering method of consumption, in all visits cannabis will be consumed by vaporization and will be either a high cannabidiol (CBD: (~10%)) and low delta-9-tetrahydrocannabinol (THC: (<1%)), or a high THC (~10%) and low CBD (<1%) variant.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High THC, Smoked | Experimental |
| |
| High THC, Vaporized | Experimental |
| |
| High CBD, Smoked | Experimental |
| |
| High CBD, Vaporized | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabis | Drug | Cannabis of (~10% THC concentration <1% CBD concentration) will be smoked. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Aortic Stiffness From Baseline Following Cannabis Consumption | Assessed via carotid-femoral pulse wave velocity (PWV) | Baseline, Post-Intervention (<2 Hours) |
| Change in Brachial Artery Vascular Function From Baseline Following Cannabis Consumption | Assessed via brachial artery flow mediated dilation (FMD) | Baseline, Post-Intervention (<2 Hours) |
| Change in Sympathetic Nervous System Activity From Baseline Following Cannabis Consumption | Assessed via microneurographic recordings of the peroneal nerve | Baseline, Post-Intervention (<2 Hours) |
| Change in Cardiac Function From Baseline Following Cannabis Consumption | Measured by echocardiography | Baseline, Post-Intervention (<2 Hours) |
| Measure | Description | Time Frame |
|---|---|---|
| Exercise Capacity | Assessed by maximal average power attainable during 20 minutes of continuous cycling exercise | Baseline, Post-Intervention (<2 Hours) |
| Heart Rate | Measured at rest and during exercise |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Guelph | Guelph | Ontario | N1G2W1 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39575727 | Derived | Cheung CP, Coates AM, Baker RE, Burr JF. Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. J Am Heart Assoc. 2024 Dec 3;13(23):e037731. doi: 10.1161/JAHA.124.037731. Epub 2024 Nov 22. | |
| 36314198 | Derived | Cheung CP, Nardone M, Lee JB, Baker RE, Millar PJ, Burr JF. Cannabis Inhalation Acutely Reduces Muscle Sympathetic Nerve Activity in Humans. Circulation. 2022 Dec 20;146(25):1972-1974. doi: 10.1161/CIRCULATIONAHA.122.062564. Epub 2022 Oct 31. No abstract available. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 11, 2020 | Dec 16, 2020 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 16, 2020 | Dec 16, 2020 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C587251 | nabiximols |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cannabis | Drug | Cannabis of (~10% THC concentration <1% CBD concentration) will be vaporized. |
|
|
| Cannabis | Drug | Cannabis of (~10% CBD concentration <1% THC concentration) will be smoked. |
|
|
| Cannabis | Drug | Cannabis of (~10% CBD concentration <1% THC concentration) will be vaporized. |
|
|
| Baseline, Post-Intervention (<2 Hours) |
| Systolic Blood Pressure | Measured at rest and during exercise | Baseline, Post-Intervention (<2 Hours) |
| Diastolic Blood Pressure | Measured at rest and during exercise | Baseline, Post-Intervention (<2 Hours) |
| Perceived Exertion | Measured during exercise | Baseline, Post-Intervention (<2 Hours) |
| Oxygen Consumption | Measure of metabolic activity | Baseline, Post-Intervention (<2 Hours) |